Evidence map›Paper›PMID 39408717›Full record

SynthesisInternational journal of molecular sciences2024

The Comparative Oncology of Canine Malignant Melanoma in Targeted Therapy: A Systematic Review of

Xiaohui He, Yu Gao, Yuqing Deng, Junying He, Ingo Nolte, Hugo Murua Escobar, Feng Yu

Abstract readSystematic Review
In one paragraph

Synthesis in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Advances in Pathogenesis and Treatment of Skin Cancer.International journal of molecular sciences · 2025
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaohui HeDepartment of Small Animal Medicine, College of Veterinary Medicine, China Agriculture University, Beijing 100193, China.
Yu GaoDepartment of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Foundation, 30559 Hannover, Germany.ORCID 0000-0001-7722-2136
Yuqing DengDepartment of Small Animal Medicine, College of Veterinary Medicine, China Agriculture University, Beijing 100193, China.
Junying HeDepartment of Small Animal Medicine, College of Veterinary Medicine, China Agriculture University, Beijing 100193, China.
Ingo NolteDepartment of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Foundation, 30559 Hannover, Germany.
Hugo Murua EscobarDepartment of Medicine, Clinic III, Hematology, Oncology and Palliative Medicine, University Medical Center Rostock, 18057 Rostock, Germany.ORCID 0000-0001-7123-7986
Feng YuDepartment of Small Animal Medicine, College of Veterinary Medicine, China Agriculture University, Beijing 100193, China.

Funding

The Talent Fund of China Agricultural University Veterinary Teaching Hospital ;China Scholarship Council (CSC) The Talent Fund of China Agricultural University Veterinary Teaching Hospital (Beijing Zhongnongda Veterinary Hospital Co., Ltd.) (Grant Number:1051-2221002) and China Scholarship Council (CSC) (Grant Number: 202006170058).
6 · The paper itself

Abstract

Canine malignant melanoma (CMM) is highly aggressive and mostly located in the oral cavity. CMM is the predominant type of canine oral malignancy and shows striking homologies with human mucosal melanoma. In comparative oncology, canine oral melanomas (COMs), as spontaneous tumor models, have the potential to acquire a unique value as a translational model of rare human melanoma subtypes. This review aims to provide a comprehensive summary of targeted therapies for canine malignant melanoma and to enrich the field of comparative oncology. Following the PRISMA guidelines, a comprehensive literature search was conducted across databases for studies from 1976 to April 2024. Studies were selected based on their relevance to targeted treatments. A total of 30 studies met the inclusion criteria. Based on the treatment approaches, the studies were further categorized into immunotherapies, small molecule signaling inhibitors, indirect kinase inhibitors, and other alternative strategies. Some treatments have been shown to result in stable disease or partial response, accounting for 29% (monoclonal antibody) and 76.5% (micro-RNA therapies) in clinical trials. Moreover, in vitro experiments of small molecule inhibitors, including cell signaling inhibitors and indirect kinase inhibitors, have shown the potential to be an effective treatment option for the development of therapeutic strategies in canine malignant melanoma. The observed response in in vitro experiments of CMM (particularly the oral and certain cutaneous subtypes) to drugs used in the treatment of human melanoma underlines the resemblance to human melanoma, therefore supporting the notion that CMM may be a valuable model for understanding rare human melanoma subtypes and exploring potential therapeutic avenues in preclinical trials. Finally, this literature review serves as a valuable resource for the development of therapeutic strategies for CMM and highlights the potential for translating these findings to human cancer treatment.

Indexed as

Disease Models, AnimalDog DiseasesMelanomaMouth NeoplasmsAnimalsAntineoplastic AgentsDogsImmunotherapyMolecular Targeted TherapyAntineoplastic AgentscanineimmunotherapymelanomamicroRNAprotease inhibitortarget therapy

Identifiers

PMID39408717
PMCPMC11476434

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.